Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M79.3Revenue $M18.1Net Margin (%)-291.0Z-Score-10.2
Enterprise Value $M54.8EPS $-1.0Operating Margin %-278.4F-Score2
P/E(ttm))0Cash Flow Per Share $0.8Pre-tax Margin (%)-291.0Higher ROA y-yY
Price/Book4.310-y EBITDA Growth Rate %0Quick Ratio1.5Cash flow > EarningsN
Price/Sales4.45-y EBITDA Growth Rate %0Current Ratio1.5Lower Leverage y-yN
Price/Cash Flow7.1y-y EBITDA Growth Rate %0ROA % (ttm)-49.3Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-111.7Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M52.1ROI % (ttm)-74.6Gross Margin Increase y-yN

Gurus Latest Trades with AVEO

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AVEOSeth Klarman 2014-12-31 Sold Out -0.07%$0.65 - $1.17
($0.91)
$ 1.5140%Sold Out0
AVEOGeorge Soros 2014-09-30 Sold Out $1.09 - $1.79
($1.26)
$ 1.5117%Sold Out0
AVEOGeorge Soros 2014-06-30 Buy $1.02 - $1.72
($1.29)
$ 1.5115%New holding49,076
AVEOSeth Klarman 2013-06-30 Reduce-0.26%$2.34 - $8.27
($4.27)
$ 1.51-183%Reduce -21.90%3,829,350
AVEOGeorge Soros 2011-12-31 Sold Out -0.0031%$14.53 - $17.35
($8.42)
$ 1.51-458%Sold Out0
AVEOSeth Klarman 2011-09-30 Add0.29%$15.12 - $20.77
($17.66)
$ 1.51-1070%Add 12.79%5,000,000
AVEOGeorge Soros 2011-09-30 Reduce-0.04%$15.12 - $20.77
($17.66)
$ 1.51-1070%Reduce -92.80%11,600
AVEOSeth Klarman 2011-06-30 Add0.78%$13.06 - $20.66
($16.79)
$ 1.51-1012%Add 25.76%4,433,010
AVEOGeorge Soros 2011-06-30 Buy 0.05%$13.06 - $20.66
($16.79)
$ 1.51-1012%New holding161,000
AVEOSeth Klarman 2011-03-31 Add1.15%$13.15 - $15.02
($14.21)
$ 1.51-841%Add 76.25%3,525,000
AVEOSeth Klarman 2010-12-31 Buy 1.68%$13.84 - $17.41
($15.14)
$ 1.51-903%New holding2,000,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AVEO is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


AVEO: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Dallas Matthew DVP, Finance 2015-01-16Sell3,075$0.8284.15view
BAILEY MICHAEL PPresident & CEO 2015-01-07Sell4,484$0.888.75view
Dallas Matthew DVP, Finance 2015-01-07Sell519$0.888.75view
Vittiglio JosephSVP, General Counsel 2015-01-07Sell4,484$0.888.75view
Gyuris JenoSVP, Chief Scientific Officer 2015-01-07Sell4,484$0.888.75view
Dallas Matthew DVP, Finance 2014-07-01Sell0$088.75view
BAILEY MICHAEL PChief Business Officer 2014-01-30Sell5,430$1.64-7.93view
Vittiglio JosephSVP, General Counsel 2014-01-30Sell5,430$1.64-7.93view
Gyuris JenoSVP, Chief Scientific Officer 2014-01-30Sell5,430$1.64-7.93view
Slichenmyer WilliamChief Medical Officer 2014-01-30Sell5,430$1.64-7.93view

Press Releases about AVEO :

    Quarterly/Annual Reports about AVEO:

    News about AVEO:

    Articles On GuruFocus.com
    Wild Card Wonders, Shopping for 52-Week Lows Sep 28 2013 
    Sleepy Sector Wakes Up - Billionaires Hold Biotechs in 52-week Low Sep 03 2013 
    comment on AVEO Mar 15 2013 
    comment on AVEO Mar 15 2013 
    Weekly CEO Buys Highlight: AVEO, ZAZA, TUES, TUES, FRAN, AKVA Dec 16 2012 
    Seth Klarman’s Baupost Group Buys Microsoft Corp., BP, Allied Nevada Gold, Sells Audiovox Corp. Aug 12 2011 
    Seth Klarman’s Baupost Group Q1 Portfolio Update; Buys ANV, SCMR, PDLI, AVEO May 14 2011 
    AVEO Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 11 2011 
    Two Picks from Seth Klarman: PDLI, AVEO Feb 22 2011 
    Hedge Fund Baupost Group buys PDLI, AVEO, ALR, Sells LSTZA, UFS, SLRC, EXXI Feb 11 2011 

    More From Other Websites
    Zacks Rank #1 Additions for Monday - Tale of the Tape May 04 2015
    United Therapeutics Falls on Q1 Loss, Misses on Revenues - Analyst Blog Apr 29 2015
    Hospira, Set to Be Acquired by Pfizer, Beats on Q1 Earnings - Analyst Blog Apr 28 2015
    AbbVie's HCV Cocktail Treatment Under FDA Priority Review - Analyst Blog Apr 24 2015
    Isis Pharmaceuticals' ISIS-TTR Effective in Extension Study - Analyst Blog Apr 23 2015
    Acorda Reports Encouraging Data on MS Drug - Analyst Blog Apr 23 2015
    Emergent BioSolutions Resumes BioThrax Manufacturing - Analyst Blog Apr 23 2015
    Capricor's CAP-1002 Gets Orphan Drug Status in the U.S. - Analyst Blog Apr 23 2015
    Eli Lilly Beats on 1Q Earnings by Wide Margin, Affirms View - Analyst Blog Apr 23 2015
    Alexion Misses Q1 Earnings Estimates, Keeps 2015 Outlook - Analyst Blog Apr 23 2015
    Zacks Rank #1 Additions for Thursday - Tale of the Tape Apr 23 2015
    Four one-time biotech underdogs are outperforming the market this year Apr 22 2015
    AVEO PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Apr 22 2015
    AVEO Names Keith S. Ehrlich as Chief Financial Officer Apr 22 2015
    AVEO Names Keith S. Ehrlich as Chief Financial Officer Apr 22 2015
    The Medicines Co.'s New Minocin Formulation Approved - Analyst Blog Apr 21 2015
    Bristol-Myers Announces Positive Data from Opdivo Study - Analyst Blog Apr 21 2015
    AVEO Pharmaceuticals (AVEO) Shares March Higher, Can It Continue? - Tale of the Tape Apr 21 2015
    Bristol-Myers' Study on Opdivo Halted on Early Success - Analyst Blog Apr 20 2015
    Oncolytics' Reolysin Gets One More Orphan Drug Status - Analyst Blog Apr 20 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK